Genscript Biotech Corporation (1548.HK)
Provides research tools, biologics development services, and engineered enzymes for life science companies.
17.28+0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+4.1%
The outlook
Genscript Biotech trades at 17.28 with strong analyst backing—seven analysts average a "Strong Buy" rating. The stock sits well above its key moving averages and sits roughly three-quarters of the way up from its 52-week low, while the average analyst price target sits about 3% above the current level.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 7 analysts
Price trendAbove its 50- & 200-day averages
52-week range77% of the way from its 52-week low to high
Price targetAvg target +3% vs current price
Analyst price target
~12-month · 7 analysts17.76average target+2.8% vs now
Now 17.28
Low 15.51High 21.04
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$37.75B
52-wk high
19.40
52-wk low
10.36
50-day avg
13.28
200-day avg
13.51
Trailing P/E
—